Immunization with reverse-genetics-produced H5N1 influenza vaccine protects Ferrets against homologous and heterologous challenge

Journal of Infectious Diseases

Volumn 194, Issue 2, 2006, Pages 159-167

  Govorkova, Elena A ^a   Webby, Richard J ^a   Humberd, Jennifer ^a   Seiler, Jon P ^a   Webster, Robert G ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; EPIDEMIC; FERRET; HEMAGGLUTINATION INHIBITION; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION; VACCINE PRODUCTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FERRETS; GENETIC ENGINEERING; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 33746141255     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/505225     Document Type: Article

References (38)

1. de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL. A pandemic warning? Nature 1997; 389:554.
2. Guan Y, Poon LL, Cheung CY, et al. H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci USA 2004; 101:8156-61.
3. de Jong MD, Bach VC, Phan TQ, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005; 352:686-91.
4. To KF, Chan PK, Chan KF, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 2001; 63: 242-6.
5. Tran TH, Nguyen TL, Nguyen TD, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004; 350:1179-88.
6. Sims LD, Ellis TM, Liu KK, et al. Avian influenza in Hong Kong 1997-2002. Avian Dis 2003; 47:832-38.
7. Monto AS. The threat of an avian influenza pandemic. N Engl J Med 2005; 352:323-5.
8. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005; 352:333-40.
9. Wood JM, Robertson JS. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2004; 2:842-7.
10. Takada A, Kuboki N, Okazaki K, et al. Avirulent avian influenza virus as a vaccine strain against a potential human pandemic. J Virol 1999; 73: 8303-7.
11. Wood JM, Major D, Daly J, et al. Vaccines against H5N1 influenza. Vaccine 1999; 18:579-80.
12. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/ 97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43.
13. Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, Webster RG. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 1999; 73:2094-8.
14. Li S, Liu C, Klimov A, et al. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis 1999; 179:1132-8.
15. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19:1732-7.
16. Webby RJ, Perez DR, Coleman JS, et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004; 363:1099-103.
17. Subbarao K, Chen H, Swayne D, et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003; 305:192-200.
18. Liu M, Wood JM, Ellis T, et al. Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics. Virology 2003; 314: 580-90.
19. Kohler G, Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 1976; 6:511-9.
20. Reuman PD, Keely S, Schiff GM. Assessment of signs of influenza illness in the ferret model. J Virol Methods 1989; 24:27-34.
21. Zitzow LA, Rowe T, Morken T, et al. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 2002; 76:4420-9.
22. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg 1938; 27:493-7.
23. Webster RG, Campbell CH. An inhibition test for identifying the neuraminidase antigen on influenza viruses. Avian Dis 1972; 16:1057-66.
24. Kida H, Ito T, Yasuda J, et al. Potential for transmission of avian influenza viruses to pigs. J Gen Virol 1994; 75(Pt 9):2183-8.
25. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103:163-71.
26. Rimmelzwaan GF, Claas EC, van Amerongen G, de Jong JC, Osterhaus AD. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 1999; 17:1355-8.
27. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191: 1210-5.
28. Govorkova EA, Rehg JE, Krauss S, et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 2005; 79:2191-8.
29. Katz JM, Lu X, Tumpey TM, Smith CB, Shaw MW, Subbarao K. Molecular correlates of influenza A H5N1 virus pathogenesis in mice. J Virol 2000; 74:10807-10.
30. World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005; 11:1515-21.
31. Lipatov AS, Webby RJ, Govorkova EA, Krauss S, Webster RG. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 2005; 191:1216-20.
32. Ada GL, Jones PD. The immune response to influenza infection. Curr Top Microbiol Immunol 1986; 128:1-54.
33. Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG. Role of specific hemagglutinin amino acids in the immunogenidty and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci USA 2005; 102:12915-20.
34. O'Neill E, Krauss SL, Riberdy JM, Webster RG, Woodland DL. Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 2000; 81:2689-96.
35. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13-7.
36. Moss P. Cellular immune responses to influenza. Dev Biol (Basel) 2003; 115:31-7.
37. McLaren C, Potter CW. Immunity to influenza in ferrets. VII. Effect of previous infection with heterotypic and heterologous influenza viruses on the response of ferrets to inactivated influenza virus vaccines. J Hyg (Lond) 1974; 72:91-100.
38. Small PA Jr, Waldman RH, Bruno JC, Gifford GE. Influenza infection in ferrets: role of serum antibody in protection and recovery. Infect Immun 1976; 13:417-20.